[ad_1] – First anthrax vaccine developed using recombinant DNA technology– Annual production capacity of up to 10 million doses at GC Biopharma’s facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ — GC Biopharma (006280.KS), a leading […]
Tag: GC Biopharma
GC Biopharma’s Varicella Vaccine Strain ‘MAV/06’ Listed in WHO Position Paper
[ad_1] Officially recognized by WHO as a standard varicella vaccine strain alongside Oka Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ — GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its […]
GC Biopharma’s Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in ‘Vaccine’
[ad_1] YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ — GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine ‘BARYTHRAX inj. […]
GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025
[ad_1] YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ — GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium […]
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
[ad_1] YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ — GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with ‘GC1130A’, an innovative new […]
